sarscov2in1

SARS-CoV-2-IN-1 is a potent inhibitor of Mpro [SARS-CoV-2 Mpro, SARS-CoV Mpro, and MERS-CoV Mpro] with IC50 values of 0.67, 0.90, and 0.58 μM, respectively.

SARS-CoV-2-IN-101 (compound 10O) is an effective orally active inhibitor of SARS-CoV-2 with an EC50 value of 0.64 µM against HCoV-229E. This compound exhibits cytotoxicity and can reduce the expression levels of HCoV-229E N protein and RNA. Additionally, SARS-CoV-2-IN-101 has broad-spectrum antiviral activity against coronaviruses.

SARS-CoV-2-IN-106 (compound 19) is a SARS-CoV-2 papain-like protease inhibitor, displaying IC50 values of 0.44 μM for papain-like proteases and 0.18 μM for viral replication.

SARS-CoV-2-IN-108 (Compound 29) is an inhibitor of SARSCoV-2 papain-like protease, with an IC50 of 0.14 µM. It can inhibit viral replication, displaying an EC50 of 0.21 µM.

SARS-CoV-2-IN-107 (Compound A7) is an inhibitor of SARS-CoV-2 3CLpro, with an IC50 of 261.3 nM. It inhibits the replication of SARS-CoV-2, exhibiting an EC50 of 11.7 μM. Additionally, SARS-CoV-2-IN-107 demonstrates anti-inflammatory activity in LPS-stimulated RAW264.7 macrophages, with a NO inhibition rate of 68.6%.

SARS-CoV-2-IN-110 (compound Bb1) is an inhibitor of SARS-CoV-2, demonstrating antiviral efficacy with an EC50 of 1.10 μM, and significantly reduced toxicity compared to Lapatinib. The compound exhibits a CC50 of greater than 100 μM against SARS-CoV-2, with a selectivity index (SI) exceeding 91.

SARS-CoV-2-IN-109 (compound 50) is an inhibitor targeting SARS-CoV, demonstrating in vivo anti-infection activity. It interferes with the interaction between the SARS-CoV-2 Spike receptor-binding domain (RBD) and the human receptor angiotensin-converting enzyme 2 (ACE2) with an EC50 of 26.5 μM, effectively blocking SARS-CoV-2 entry into VeroE6 cells (ECS50=17.0 μM). The compound has a CC50 greater than 100 μM in VeroE6 cells.

SARS-CoV-2-IN-105 (Compound 4a) is an inhibitor of SARS-CoV-2, with an EC50 value of 0.69 μM.

SARS-CoV-2-IN-111 (compound 77) is a highly effective inhibitor of SARS-CoV-2, exhibiting an IC50 of 0.67 μM. It markedly decreases the presence of SARS-CoV-2 within Vero cells.

SARS-CoV-2-IN-115 (Compound 3e) is a potent inhibitor of SARS-CoV-2, showing strong antiviral activity in infected Calu-3 cells with an EC50 of 1.7 μM. It effectively inhibits human dihydroorotate dehydrogenase (HsDHODH) activity with an IC50 of 1.5 μM. Importantly, SARS-CoV-2-IN-115 maintains immune response without affecting the proliferation of CD4 T cells.

SARS-CoV-2-IN-114 (Compound 36) is an antiviral agent with significant activity against both the original SARS-CoV-2 strain and the Delta variant. It inhibits the cytopathic effect (CPE) of the original SARS-CoV-2 strain with an EC50 of 0.29 μM and 5.77 μM for the Delta variant. SARS-CoV-2-IN-114 exhibits low cytotoxicity, making it suitable for coronavirus research.

SARS-CoV-2-IN-112 (Compound 6f) is an orally active, non-peptidic inhibitor of the SARS-CoV-2 main protease with an IC50 of 6.48 μM. It exhibits potent antiviral activity while demonstrating low cytotoxicity against WI-38 cells (IC50: 53.81 μM). SARS-CoV-2-IN-112 is applicable for coronavirus COVID-19 research.

SARS-CoV-2-IN-113 (Compound 24) is a sulfonyl hydrazine derivative that exhibits antiviral activity against SARS-CoV-2 infection, with an IC50 of 8.320 μM. It effectively inhibits the entry and replication of SARS-CoV-2 by downregulating genes and proteins such as Spike, ACE-2, and RdRp. SARS-CoV-2-IN-113 shows high selectivity and low cytotoxicity, making it a valuable candidate for COVID-19 research.

SARS-CoV-2-IN-117 (Compound C19) is an inhibitor of the SARS-CoV-2 E protein. It effectively disrupts the interaction between the SARS-CoV-2 E protein and the host ZO-1 PDZ2 domain. This compound exhibits potent antiviral activity and significantly reduces viral replication. SARS-CoV-2-IN-117 is applicable for COVID-19 research.

SARS-CoV-2-IN-118 (compound A.13) is an inhibitor that targets the translation initiation element SL1 of SARS-CoV-2 RNA.

SARS-CoV-2-IN-116 (Compound (S,S)-4) is a highly selective inhibitor of angiotensin-converting enzyme 2 (ACE2) with a pIC50 of 7.61. It prevents the binding of the SARS-CoV-2 spike protein to ACE2 and holds promise for research related to COVID-19.

SARS-CoV-2-IN-10 is a powerful and non-toxic inhibitor of SARS-CoV-2 3CL protease, with IC50 and EC50 values of 0.13 nM and 1.03 nM, respectively. The SARS-CoV-2 3C-like protease (3CLpro) is critical for viral replication and serves as an ideal target for intervention. By targeting the SARS-CoV-2 3CL protease, SARS-CoV-2-IN-10 has the potential to facilitate the development of effective antiviral drugs specific to SARS-CoV-2.

SARS-CoV-2-IN-11 is a highly potent and non-toxic inhibitor of the 3C-like protease (3CLpro) of SARS-CoV-2, with IC50 and EC50 values of 0.17 nM and 1.45 nM, respectively. This compound targets the essential viral replication enzyme (3CLpro), making it an attractive candidate for intervention strategies and holds significant promise in the development of specific antivirals against SARS-CoV-2.

SARS-CoV-2-IN-14 is a potent and oral inhibitor of SARS-CoV-2 (IC50:0.39 μM), which is an analogue of niclosamide. SARS-CoV-2-IN-14 was more stable than niclosamide in the determination of human plasma and liver S9 enzyme. Oral administration of SARS-CoV-2-IN-14 can improve its bioavailability and half-life.

SARS-CoV-2-IN-16 (Compound 12) is a potent inhibitor of SARS-CoV-2 nucleocapsid protein (NPro) with antiviral activity (EC50 = 3.69 μM) and binds to NPro with a low Kd value of 7.82 μM, indicating its effectiveness as an NPro ligand [1].

SARS-CoV-2-IN-15 (compound 11) is a niclosamide analogue exhibiting greater stability in human plasma and liver S9 enzyme assays compared to niclosamide. It enhances bioavailability and half-life upon oral administration and is a potent SARS-CoV-2 inhibitor with an IC50 of 0.49 μM [1].

SARS-CoV-2-IN-13 (compound 5) is an analogue of niclosamide, displaying greater stability in human plasma and liver S9 enzymes assay. It improves bioavailability and half-life when administered orally and is a potent SARS-CoV-2 inhibitor with an IC50 of 0.057 μM [1].

SARS-CoV-2-IN-18 (Compound 26) is a powerful inhibitor of the SARS-CoV-2 3C-like protease, with an IC50 of 45 nM [1].

SARS-CoV-2-IN-17 (Compound 16) is a highly effective inhibitor of the SARS-CoV-2 nucleocapsid protein (NPro), demonstrating potent antiviral activity with an EC50 value of 2.18 μM and binding to NPro with a low Kd value of 7.82 μM, underscoring its potency as a NPro ligand [1].